Core Insights - The 2025 Q4 report from Changcheng Pharmaceutical Industry Selected Fund indicates a "high-low-tail" oscillating upward pattern in A-shares, while H-shares are experiencing a consolidation phase, with December showing a significant underperformance compared to A-shares, driven by policy, liquidity, and profit expectations [1][3] Summary by Category Market Performance - A-shares exhibited a "high-low-tail" oscillating upward pattern in Q4 2025, while H-shares faced a consolidation phase, with December showing a notable underperformance against A-shares [1][3] - The performance of both markets is influenced by policy, liquidity, and profit expectations, with H-shares additionally pressured by overseas liquidity and funding preferences [1][3] Investment Strategy - The fund manager suggests that many innovative pharmaceutical stocks currently offer good value for money [1][3] - The investment strategy has been adjusted to form two allocation lines: "already BD" and "not yet BD" [1][3] - "Already BD" stocks focus on the importance of MNC internal pipelines and the global core clinical advancement rhythm, while "not yet BD" stocks are based on the global competitiveness and scarcity of core pipelines [1][3] - The strategy also considers the nearing end of the impact of centralized procurement on financial statements and the overall verification phase of innovative transformation for generic-to-innovative companies, leading to increased attention on these companies [1][3]

截至收盘，恒生指数报收26585.06点，上涨97.55点，涨幅0.37%。 昨晚，美股市场全线大跌，道指狂跌870点，纳指大跌561点，这也为今日（1月21日）港股表现蒙上阴 影。 不过，港股市场今日下午展开反攻，恒生科技指数涨超1%。 市场热点方面，机器人概念股全线走强。其中，微创机器人-B（HK02252）涨超17%，卧安机器人 （HK06600）涨超10%，优必选（HK09880）涨超4%。 资金方面，截至收盘，南向资金净买入港股超139亿港元。 展望后市： 华泰证券认为，当前推动一季度市场反弹的核心因素并未发生根本性变化，如金融条件整体偏宽松、外 资和南向共振回流、盈利预期上修、AH比价下港股性价比再度凸显等。尤其是考虑到目前市场对港股 后续表现尚未形成共识，一季度延续反弹依然可期，建议重点关注港股布局机会。行业上，现阶段重点 关注AI链（半导体、软件）及创新药。 华西证券预计，未来一段时间港股市场风格和2025年一季度和二季度风格相比出现进一步的转变，仍然 是2025年涨幅偏小、受外围市场影响较小、基本面韧性较好的资产存在一些结构性机会。 恒生科技指数报收5746.30点，上涨62.86点，涨幅1 ...

Core Insights - The current market environment in 2026 differs significantly from 2015, with the recent rise to 4100 points driven by solid industrial foundations and profit support rather than just liquidity and risk appetite [1][5][6] - Opportunities in the market are emerging from accelerated global AI capital expenditure, with Chinese companies actively participating in various segments of the AI industry chain [1][6] - The ongoing geopolitical tensions, abundant liquidity, and economic recovery are contributing to rising prices of upstream resources, creating new investment opportunities [1][6] Market Dynamics - The A-share market is transitioning from a phase primarily driven by liquidity and risk appetite to one where both profits and valuations are expected to drive growth [2][7] - Recent increases in retail investor participation have led to heightened market sentiment, necessitating regulatory measures to ensure stability [2][7] - Short-term market corrections may occur due to over-exuberance, but patience and careful stock selection are advised for investors [2][7] Sector Focus - Continued attention is recommended for sectors such as AI computing power, semiconductors, and export-oriented industries like non-ferrous metals, electric grid equipment, and engineering machinery [2][7] - In the context of inflationary pressures, sectors like innovative pharmaceuticals and non-bank financials are suggested for consideration [2][7] Thematic Investment Opportunities - AI applications and commercial aerospace are highlighted as attractive investment themes, particularly after recent adjustments that may have alleviated short-term overheating [3][8] - The commercial aerospace sector, supported by strong policy backing and macro narratives like SpaceX, is expected to see continued upward momentum [3][8] - High-risk investors are encouraged to identify quality leaders within these sectors during periods of adjustment for long-term gains [3][8]

Group 1 - The Hong Kong Technology ETF (513020) rose over 0.7% on January 21, with a focus on the AI industry as a key driver for future performance [1] - Major Hong Kong tech companies are accelerating the integration of AI into their business ecosystems, with Alibaba leveraging its Qianwen platform for product deployment in e-commerce and transportation, while Tencent is enhancing its WeChat ecosystem to promote AI mini-programs and applications in education [1] - The Hong Kong market is seeing a concentration of leading semiconductor companies, and the recent stable performance of domestic GPU, large model, and hard tech companies post-listing suggests a continued rhythm of quality tech firms going public in Hong Kong [1] Group 2 - The Hong Kong Technology Index has outperformed the Hang Seng Technology Index, particularly in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors, with a cumulative return of 224.25% from the end of 2014 to the end of 2025, exceeding the Hang Seng Technology Index's 83.87% by over 140% [2] - The Hong Kong Technology Index has consistently outperformed other indices, including the Hang Seng Internet Index, the Hang Seng Internet Technology Index, and the Hang Seng Healthcare Index [2]

Group 1 - The JPMorgan Healthcare Conference (JPM2026) commenced on January 12 in San Francisco, showcasing 24 Chinese innovative pharmaceutical companies through main stage presentations and Asia-Pacific sessions [1] - Notable companies such as BeiGene, Zai Lab, Ascentage Pharma, and Legend Biotech presented their latest research and commercialization achievements, alongside CXO companies like WuXi AppTec and WuXi Biologics [1] - The report titled "2026 Global M&A Annual Outlook" indicates that global M&A transaction volume surged to $5.1 trillion in 2025, with the healthcare sector leading with a 44% increase [1] Group 2 - Analysts predict that medium-sized transactions valued between $5 billion and $15 billion will remain active in 2026 [1] - The Hang Seng Biotechnology Index focuses on innovative drug "crown jewels," highlighting three main advantages: concentration of leading companies, scarcity of futures liquidity, and high elasticity & high Sharpe ratio [1] - Investors looking for convenient access to core leaders in innovative pharmaceuticals are encouraged to consider the Hang Seng Biotechnology ETF (520933) for streamlined investment [1]

创新药ETF国泰（517110）跟踪的是SHS创新药指数（931409），该指数从沪深港三地市场中选取涉及 生物医药、化学制药等领域的具有创新能力的医药上市公司证券作为指数样本，重点聚焦研发实力强、 成长性好的公司，以反映中国创新药行业上市公司证券的整体表现，并侧重于成长型投资风格。 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产品 要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 1月21日，创新药ETF国泰（517110）盘中涨超1%，市场关注行业出海与业绩亮点。 华鑫证券指出，2025年是中国创新药出海具有标志性意义的一年，全年BD出海授权交易总金额达到 1356.55亿美元，首付款70亿美元，交易数量157起，均达历史新高。进入2026年，中国创新出海迎来开 门红，持续落地的BD交易验证了中国创新药的全球竞争力，支撑长线资金信心。展望2026年，创新仍 是 ...

Group 1 - The A-share market saw all three major indices rise on January 21, with the ChiNext 50 ETF (Hua Xia, 159367) increasing by 0.93%. Notable stocks included Sanhuan Group, which rose over 6%, Xiechuang Data, which increased over 5%, and Jingjia Micro, which gained over 4% [1] - The State Council's press conference highlighted a positive outlook for small and medium-sized enterprises (SMEs) in China by 2025, with key indicators showing significant growth: the added value of industrial SMEs increased by 6.9% year-on-year, and the SME export index has been in an expansion zone for 21 consecutive months [1] - The cultivation of specialized and innovative enterprises has yielded substantial results, with 17,600 "little giant" enterprises and over 140,000 specialized and innovative SMEs established, alongside more than 600,000 technology and innovation-oriented SMEs. The R&D intensity of "little giant" enterprises reached 7%, with an average of 26.6 invention patents per entity [1] Group 2 - The ChiNext 50 Index focuses on sectors such as information technology, new energy, financial technology, and pharmaceuticals, primarily consisting of leading technology companies in areas like optical modules, chips, new energy batteries, and innovative drugs. These sectors align with national policy directions and global technological trends, showcasing high growth potential and innovation [2] - The ChiNext 50 ETF (Hua Xia, 159367) offers two core advantages: a 20% price fluctuation limit, providing greater trading flexibility compared to traditional broad-based indices, and low management fees of 0.15% and custody fees of 0.05%, which effectively reduce investment costs [2]

此次合作立足长期视角，以服务实体经济和产业升级为核心导向，在依法合规、审慎稳健的前提下，探 索国际金融资源与医疗健康产业发展的深度融合，为具备创新能力和成长潜力的优质项目提供更加专 业、耐心的资本支持。 当前，医疗健康产业正处于多重因素叠加驱动的发展窗口期。一方面，人口老龄化趋势持续加深，慢性 病管理、精准诊疗和高质量医疗服务需求不断上升；另一方面，生物医药技术、医疗器械工程和数字医 疗的快速进步，正在重塑研发模式、诊疗方式和服务体系。在政策层面，各国持续完善医疗保障和产业 支持体系，为创新成果转化和产业升级创造了更加有利的环境。这些因素共同构成了医疗健康产业中长 期发展的坚实基础。 在这一背景下，医疗健康创新投资逐渐成为兼具社会价值与经济价值的重要方向。创新药领域围绕靶向 治疗、免疫治疗和新型生物技术不断取得突破，高端医疗器械在国产替代和技术升级进程中加速发展， 医疗服务体系则在专科化、数字化和精细化管理方面不断深化。这些变化不仅提升了医疗效率和服务质 量，也为长期资本参与提供了更加清晰的成长逻辑。 汇友联盟长期关注与民生改善和产业升级密切相关的投资方向，在医疗健康领域坚持以技术壁垒、临床 价值和可持续商业 ...

Group 1 - The core viewpoint is that the Hong Kong stock market is gathering leading H-share semiconductor companies, and the recent stable performance of domestic GPU, large model, and hard technology companies post-listing is expected to continue attracting quality tech enterprises to Hong Kong, providing ongoing incremental targets for the Hong Kong tech sector [1] - Investment strategies suggest that due to strict regulations and cooling sentiment in the A-share market, Hong Kong tech heavyweight stocks are likely to benefit from the upcoming AI product release window, with "northbound capital" potentially becoming more active in seeking advantageous assets in Hong Kong, indicating that Hong Kong stocks may outperform A-shares in the short term [1] - Leading tech companies in Hong Kong are accelerating the integration of AI with their business ecosystems, such as Alibaba advancing productization in core scenarios like e-commerce and transportation using its Qianwen platform, and Tencent enriching AI applications through its WeChat ecosystem [1] Group 2 - The Hong Kong Stock Connect Technology Index is overweight in sectors like new energy vehicles, innovative pharmaceuticals, and semiconductors compared to the Hang Seng Technology Index, showing a cumulative return of 224.25% from the base date at the end of 2014 to the end of 2025, significantly outperforming the Hang Seng Technology Index, which has a return of 83.87% [2] - The Hong Kong Stock Connect Technology Index has consistently outperformed similar indices, including the Hang Seng Internet Technology Index and the Hang Seng Healthcare Index, indicating its strong performance in the long term [2]

Core Viewpoint - The market is currently experiencing a mild adjustment phase after a period of continuous gains, with significant divergence in sector performance. The focus is shifting from event-driven themes to fundamentals, particularly in the technology growth sector, which remains the main driver of the spring market rally [1][2]. Group 1: Market Performance - The Shanghai Composite Index entered a consolidation phase after a series of gains, with a total decline in over 3,100 stocks and a trading volume shrinking to 2.8 trillion [1]. - The divergence in sector performance is notable, with differences in gains and losses exceeding 5% between leading and lagging sectors [1]. - The current market adjustment is viewed as a healthy correction that could facilitate further development of the rally, emphasizing the importance of maintaining trading volume and sector rotation [1]. Group 2: Sector Focus - The technology and materials sectors are expected to dominate in January, with a focus on themes such as commercial aerospace, brain-computer interfaces, and low-altitude economy [2]. - The rise in raw material prices, driven by technological investment trends, presents opportunities in small metals, energy metals, and new chemical materials [2]. - High-dividend traditional sectors are also suggested for left-side attention, anticipating a rebound during the annual report season in March-April [2]. Group 3: Specific Opportunities - AI hardware is projected to experience significant growth, with the peak of AI applications expected in 2026, indicating a transition from quantity to quality in AI applications [2]. - The trend of robot localization and integration into daily life is anticipated to continue, with opportunities arising in sensors, controllers, and dexterous hands as the market evolves [2]. - The semiconductor industry is expected to see continued domestic growth, with a focus on semiconductor equipment, wafer manufacturing, materials, and IC design [2]. - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to persist through 2026 [2]. - The innovative drug sector is entering a recovery phase after four years of adjustment, with positive net profit growth expected to continue into 2026 [2].